Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 403-411

  Holmes, Frankie Ann ^a,b   Valero, V ^a   Walters, R S ^a   Theriault, R L ^a   Booser, D J ^a   Gibbs, H ^a   Fraschini, G ^a   Buzdar, A U ^a   Willey, J ^a   Frye, D ^a   Asmar, L ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Doxorubicin; Paclitaxel anthracycline combination; Schedule

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INFUSION; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SEVERITY OF ILLNESS INDEX; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032954113     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008360406322     Document Type: Article

References (33)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
2. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-1805.
3. Reichman BS, Seidman AD, Crown JPA et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
4. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
5. Mackay B, Ewer MS, Carrasco CH et al. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994; 18: 203-11.
6. Zubrod C, Schneiderman M, Frei E III et al. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and trimethylene thiophosphoramide. J Chronic Dis 1960; 11: 7-36.
7. Holmes FA, Madden T, Newman RA et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 2713-21.
8. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 141-53.
9. Hayward JL, Carbone PP, Heuson JC et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-8.
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
11. Fisherman JS, Cowan KH, Noone M et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 774-82.
12. Sledge GW Jr, Neuberg D, Ingle J et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1997; 16: 1a (Abstr 2).
13. Gibbs H, Ewer M, Holmes F et al. Cardiac monitoring during administration of taxol-doxorubicin chemotherapy in patients with metastatic breast cancer: A preliminary report. Proc Am Soc Clin Oncol 1992; 11: 86 (Abstr 170).
14. Hortobagyi GN, Gutterman JU, Blumenschein GR et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide and BCG. Cancer 1979; 43: 1225-33.
15. Blumenschein GR, Hortobagyi GN, Richman SP et al. Alternating noncross-resistant combination chemotherapy and active non-specific immunotherapy with BCG or MER BCG for advanced breast cancer. Cancer 1980; 45: 742-9.
16. Legha S, Buzdar AU, Hortobagyi GN et al. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 1979; 91: 847-52.
17. Sledge GW Jr. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22 (Suppl 12): 123-5.
18. Pestolazzi BC, Solos GA, Choke PL et al. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 1993; 71: 1797-1800.
19. Hahn SM, Liebmann JE, Cook J et al. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 1993; 72: 2705-11.
20. Madden T, Newman RA, Antoun G et al. Paclitaxel effects on topoisomerase II transcription and activity in human breast cancer cell lines. Proc Am Assoc Cancer Res 1996; 37: 358-9 (Abstr 2446).
21. Gianni L, Munzone E, Capri G et al. Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
22. Gehl J, Boesgaard M, Paaske T et al. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 1996; 7: 687-93.
23. Frassineti GL, Zoli W, Silvestro LA et al. Paclitaxel plus doxorubicin in breast cancer: An Italian experience. Sem Oncol 1997; 24 (Suppl 17): S17-19-S17-25.
24. Schwartsmann G, Mans DR, Menke CH et al. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology 1997; 11 (Suppl 3): 24-9.
25. Cazap E, Ventriglia M, Rubio G et al. Taxol plus doxorubicin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1996; 15: 146 (Abstr 248).
26. Conte PF, Baldini E, Gennari A et al. Dose-finding study and pharmacokinetics of epirubicin plus paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510-8.
27. Lück H-J, Thomssen C, duBois A et al. Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1997; 24 (Suppl 17): S17-35-S17-39.
28. Catimel G, Spielmann M, Dieras V et al. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety. Semin Oncol 1996; 23 (Suppl 1): 24-27.
29. Di Costanzo F, Sdrobolini A, Bilancia D et al. Phase I-II trial of mitoxantrone and taxol in advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: 139 (Abstr 220).
30. Hortobagyi GN, Willey J, Rahman Z et al. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 1997; 24 (Suppl 17): S17-65-S17-68.
31. Von Hoff DD. The taxoids: Same roots, different drugs. Semin Oncol 1997; 24 (Suppl 13): S13-3-S13-10.
32. D'Incalci M, Schüller J, Colombo T et al. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations. Semin Oncol 1998; 25 (Suppl 13): 16-20.
33. Nabholtz, JM. 21st Annual San Antonio Breast Cancer Symposium, 13 December 1998. San Antonio, TX.